At the beginning of the eighteenth century, most physicians recognized cancer as an aggressive process that gradually spreads, leading to cachexia and death. Thyroid malignancies had long been underestimated because the majority of the population of West Europe suffered from diffuse goiters that masked malignant processes in the neck. Moreover, the life expectancy at that time was very low (about 37-40 years), so the majority of people died of other causes before metastatic thyroid cancer could develop and manifest. Nevertheless, in 1817, French dermatologist Jean Louis Alibert described the first case of a malignant tumor involving the thyroid gland. From the 1820s the number of case reports describing thyroid cancer increased. Even though Jean Claude Recamier described in 1829, secondary lesions on various organs in patients with thyroid malignancies were not themselves considered malignant until 1876.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096462 | PMC |
http://dx.doi.org/10.3389/fendo.2024.1354750 | DOI Listing |
J Cancer
January 2025
Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China.
Breast cancer continues to be a significant global health challenge due to its heterogeneity and propensity for therapeutic resistance. The current tumor, node, and metastasis (TNM) staging and molecular classification systems are limited in capturing the full biological complexity of breast cancer. Myeloid differentiation primary response protein 88 (MyD88), a key adaptor protein in inflammatory signaling pathways, has been implicated in various oncogenic processes.
View Article and Find Full Text PDFThis review focuses on the latest advancements in using biomarkers to diagnose, predict outcomes, and guide the treatment of different types of thyroid cancer, such as anaplastic, papillary, medullary, and follicular thyroid carcinoma. We highlight the key role of both traditional and new biomarkers in improving the treatment of these cancers. For anaplastic thyroid cancer, biomarkers are crucial for detecting distant metastases and making treatment decisions.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Pathology and Laboratory Medicine, College of Medicine, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
MicroRNAs (miRNAs) can function as either tumor suppressors or oncogenes. This study explores the role of miR-675 in ovarian cancer (OC) using OC cell lines and an orthotopic mouse model. We demonstrate that miR-675 expression inhibits primary tumor growth and metastasis by targeting TGFβ1, suppressing epithelial to mesenchymal transition (EMT), and attenuating the TGFβ signaling pathway.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Spinal Surgery, Tianjin Union Medical Center, Tianjin, China.
Whether autoimmune diseases caused any effects on the risk of cancers remained yet clarified. This study aimed to investigate the causal effect of autoimmune diseases on pan-cancers through mendelian randomization (MR) analysis. The GWAS summary datasets of 10 autoimmune diseases were derived from the IEU or UK biobank website.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Urology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China.
Pro-apoptotic coiled-coil domain containing 8 (CCDC8) has been linked to tumor progression and metastasis, yet its prognostic significance and underlying molecular mechanisms in bladder cancer remain to be elucidated. This study utilized raw data from public databases along with a single-center retrospective case series. We performed bioinformatics analysis and immunohistochemistry to investigate the biological landscape of CCDC8 in various tumors, with a particular focus on bladder cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!